Every claim on this site traces back to a published study, a federal safety communication, or a named expert's clinical work. This page collects those sources in plain language — what each one found, and why it matters for skin on a GLP-1 — so you (or your dermatologist) can go read the original.
This list grows as we publish. It currently reflects every source cited in "Why Your Skin Changes on GLP-1" and "Is High-Dose Biotin Safe on a GLP-1?", plus additional sources we consider foundational to this topic even before their dedicated articles go live.
Clicking an outbound source below will ask you to confirm you're leaving pellvara.com — we just want to be clear you're headed to an outside site like PubMed, the FDA, or a journal publisher.
Mechanism & Receptor Biology
Why GLP-1 therapy changes skin structure in the first place
Ridha Z, Fabi SG, Zubair R, Dayan SH — "Decoding the Implications of Glucagon-like Peptide-1 Receptor Agonists on Accelerated Facial and Skin Aging." Aesthetic Surgery Journal, 44(11):NP809–NP818, 2024.
Documents that GLP-1 receptors exist on skin cells themselves — adipose-derived stem cells and dermal fibroblasts — meaning the medication can act directly on skin, not only indirectly through fat loss elsewhere in the body.
Paschou SA, et al. — "GLP-1RA and the Possible Skin Aging." Endocrine, 2025.
Connects GLP-1 receptor activation on skin cells to reduced protective cell signaling, increased oxidative stress, and measurable changes in collagen and elastic fiber density on biopsy.
Extends the receptor mechanism further — finds GLP-1 receptors specifically on keratinocytes and in hair follicle regions, relevant to both dryness and hair thinning on therapy.
Gupta AK, Teasell EM, Economopoulos V, Mirmirani P — "GLP-1 Therapies and Hair Loss: A Systematic Review of Current Evidence and Implications for Counseling." SAGE Journals, 2026.
Found roughly a threefold increase in reported hair loss among GLP-1 patients compared with placebo across pooled clinical trial data.
Narla S, Narla RR, Corbett JA — "GLP-1 Receptor Agonists: Mechanism of Action and Pathways in Skin Health." Journal of the American Academy of Dermatology CME Part 1. February 2026. PMID 41707707.
JAAD-designated CME: documents GLP-1R expression on keratinocytes, fibroblasts, and sebaceous glands, and maps the physiologic pathways through which receptor activation influences skin structure and function — the most current formal summary of the direct skin mechanism.
Narla S, Narla RR — "Clinical Evidence and Safety of GLP-1 Receptor Agonists in Dermatology." Journal of the American Academy of Dermatology CME Part 2. February 2026. PMID 41698604.
Covers emerging clinical evidence for GLP-1 receptor agonists in psoriasis, hidradenitis suppurativa, and wound healing — establishing the therapeutic context alongside the skin-change profile documented in Part 1.
Haykal D, et al. — "Aesthetic consequences of GLP-1-induced weight loss." Journal of Cosmetic Dermatology. 2025. DOI 10.1111/jocd.16716.
Peer-reviewed review documenting the specific aesthetic consequences of rapid fat reduction on GLP-1 therapy: facial volume loss, skin laxity, and premature aging changes that occur faster than skin can structurally adapt.
Burke KR, et al. — "GLP-1R expression in skin: keratinocyte proliferation, differentiation, and barrier function." Skin Appendage Disorders. October 2025. DOI 10.1159/000544023.
Confirms GLP-1 receptor expression plays a direct role in skin barrier maintenance and cytoprotection — supporting the mechanism by which receptor activation affects skin function independently of weight change.
Persson A, et al. — "Dermatologic profile of GLP-1 receptor agonists: a systematic review." Diseases. 2025;13(5):127.
Systematic review across 51 studies: documents the full range of GLP-1 cutaneous effects, including both immunomodulatory benefits and adverse skin changes — the most comprehensive survey of the dermatologic profile to date.
Varani J, et al. — "Decreased Collagen Production in Chronologically Aged Skin." American Journal of Pathology. 2006;168(6):1861–1868. PMC1606623.
Establishes the slow timeline of skin's structural response to change: fibroblasts produce collagen over weeks to months, not days. The foundational basis for why GLP-1-driven fat loss causes lasting visible laxity rather than rapid adaptation.
What GLP-1 therapy does to intake, absorption, and nutrient status
Butsch WS, et al. — "Nutritional Deficiencies and Muscle Loss in Adults with Type 2 Diabetes Using GLP-1 Receptor Agonists: A Retrospective Observational Study" (n=461,382). Obesity Pillars, 2025.
The largest cohort study to date on this question: 12.7% of patients developed a diagnosable nutritional deficiency within 6 months of starting therapy, rising to 22% by 12 months — vitamin D, iron, and calcium/protein intake most affected. Ferritin levels were 26–30% lower in GLP-1 users relative to comparators.
Urbina J, Salinas-Ruiz LE, Clapp B — "Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review." Clinical Obesity, 2026.
A 2026 narrative review corroborating the deficiency pattern across semaglutide, liraglutide, and tirzepatide: by 6 months, 12.7% of patients had a new nutritional deficiency diagnosis (vitamin D most common at 7.5%), with 2% developing iron-deficiency anemia and 1.5% documented muscle loss.
Not yet cited on-siteReserved for Cluster 3 nutrition pillarRead the study →
Cegarra L, et al. — "Calcium Is a Noncompetitive Inhibitor of DMT1 on the Intestinal Iron Absorption Process." American Journal of Physiology-Cell Physiology, 323(6):C1791–C1806, 2022.
Shows calcium blocks the same transporter (DMT1) that carries iron into the body — the reason our own formulation work keeps calcium and iron on separate timing windows rather than combining them.
Not yet cited on-siteReserved for Cluster 3 nutrition pillarRead the study →
Nutrition & Biotin
The FDA warnings, the clinical research, and what they mean for GLP-1 patients
U.S. Food & Drug Administration — "Biotin (Vitamin B7): Safety Communication — May Interfere with Lab Tests." November 28, 2017.
First formal federal warning that high-dose biotin interfered with a troponin immunoassay, resulting in a falsely low cardiac marker reading and incorrect treatment for a patient evaluated for a heart attack.
U.S. Food & Drug Administration — "UPDATE: The FDA Warns that Biotin May Interfere with Lab Tests." November 5, 2019.
Expanded federal warning confirming interference across multiple assay types — thyroid function panels, ferritin, hormone levels, and cardiac markers — and documenting that labs had not uniformly corrected for the issue two years after the initial warning.
Butsch WS, et al. — "Nutritional Deficiencies and Muscle Loss in Adults with Type 2 Diabetes Using GLP-1 Receptor Agonists" (n=461,382). Obesity Pillars, 2025. PMC12205620.
Retrospective cohort of 461,382 patients: ferritin levels were 26–30% lower in GLP-1 users relative to comparators — population-scale iron depletion relevant here because ferritin is a standard GLP-1 monitoring lab and high-dose biotin can falsely elevate it. See the full entry in Nutrition & Deficiency above for the complete deficiency findings.
Lipner SR — "Rethinking biotin therapy for hair, nail, and skin disorders." Journal of the American Academy of Dermatology. 2018;78(6):1236–1238.
Argues the clinical evidence for biotin supplementation in hair loss is weak in the absence of true deficiency, and raises concern that interference risk to patients on routine lab monitoring has been systematically underappreciated.
Chang MJ, Lipner SR — "Altmetric analysis of biotin in scholarly outputs following the biotin FDA warning." Journal of the American Academy of Dermatology. 2019.
Of 119 biotin-related academic articles published in the two years following the 2017 FDA warning, only 5% mentioned the FDA communication — documenting how poorly the safety signal propagated through clinical literature.
Lipner SR — "Update on Biotin Therapy in Dermatology: Time for a Change." Journal of Drugs in Dermatology. 2020;19(12):1264–1265.
Survey of 113 dermatologists found 51% were still prescribing biotin two years after the 2017 FDA warning — establishing a documented clinical-inertia gap between the warning and practice change.
Waqas B, Wu A, Yim E, Lipner SR — "A survey-based study of physician practices regarding biotin supplementation." Journal of Dermatological Treatment. 2020.
Documents the gap between FDA warning issuance and clinical practice change: the majority of physicians surveyed were not routinely asking patients about biotin supplementation prior to ordering labs.
Mager LE, et al. — "Biotin Supplements for Hair and Nail Regrowth: A Caution for Oncologists." JCO Oncology Practice. 2026.
More than half of patients who presented with treatment-related hair loss had self-started biotin supplements without disclosing it to their care team — a monitored population with regular labs, paralleling the GLP-1 patient situation directly.
American Association for Clinical Chemistry — "Guidance Document on Biotin Interference in Laboratory Tests." 2020.
Establishes the 5,000 mcg threshold above which biotin interference with commonly used biotinylated immunoassays is formally documented — the laboratory standard against which supplement doses are evaluated.
Brinks AL, Needle CD, Kearney C, Shapiro J, Lo Sicco KI — "Supratherapeutic vitamin D with a hair nutraceutical: A case report." JAAD Case Reports. 2025;63:115–117.
Case report documenting vitamin D toxicity from a leading hair nutraceutical — and in characterizing the product's full ingredient profile, independently confirms its 3,000 mcg biotin content: the standard dose in leading hair supplements marketed to patients experiencing hair thinning.
Professional commentary from our named advisors — not an independent publication
Martina M. Cartwright, PhD, RD — clinical commentary drawn from her presentation, "Essential Nutrients for Skin Health," American Academy of Dermatology (AAD) Annual Meeting, 2024.
Our scientific advisor's professional view on how specific deficiencies common in GLP-1 patients — zinc, vitamin C, copper, biotin, omega-3 — show up as visible skin, hair, and wound-healing symptoms. This reflects Dr. Cartwright's direct clinical input to Pellvara; it is not an independently published paper, so there's no outside source to link to. We're confirming the presentation details with her directly and will update this entry — or convert it into a full Q&A with its own citation — once confirmed.
Why reduced dietary fat intake shows up as dryness and barrier breakdown
Boelsma E, Hendriks HFJ, Roza L — "Nutritional Skin Care: Health Effects of Micronutrients and Fatty Acids." American Journal of Clinical Nutrition, 73(5):853–864, 2001.
Foundational, widely-cited review establishing the link between dietary micronutrients and fatty acids and measurable skin health outcomes — the basis for the "diet affects skin barrier" framing used throughout this site.
This link goes to an outside source — a journal, publisher, or government site. We link out because we want you to see the original research, not just take our word for it.